Ontario (Rajeev Sharma): Cancer patients in Ontario are beginning to benefit from quicker access to advanced drug therapies as the provincial government rolls out a new initiative aimed at cutting lengthy approval delays for publicly funded medications.
The Funding Accelerated for Specific Treatments (FAST) program, introduced last year, is now being implemented across the province. Health officials say it is already helping patients obtain life-prolonging cancer drugs months earlier than the conventional approval pathway, which can stretch close to three years.
Under the new system, six innovative treatments covering a range of cancers — including lung, prostate, leukemia, lymphoma, colorectal and liver — have been cleared for early funding since October. Provincial leaders say additional medications will be added in the coming months.
Dr. Keith Stewart, director of Princess Margaret Cancer Centre and vice-president for cancer services at University Health Network, said the shorter timeline is a significant breakthrough for patients who often have limited time.
“For many people, waiting an extra year can be devastating,” Stewart said. “Once a treatment is known to work, having to sit through prolonged administrative processes adds enormous stress and anxiety.”
Historically, Canadians face some of the longest waits in the developed world for new publicly funded medicines. While drugs may receive regulatory approval relatively quickly, funding negotiations and policy decisions frequently add another 18 to 24 months before patients can access them through public programs.
Stewart said these delays can push families into difficult choices, including paying out-of-pocket or seeking treatment overseas. In recent years, some Ontario patients have considered traveling abroad to obtain therapies already available in other countries.
Many of the newer treatments also come with steep price tags. Some medications can cost thousands of dollars per dose, while advanced cellular therapies may exceed hundreds of thousands for a single course. Despite the expense, doctors say timely access can dramatically improve outcomes and survival rates.
Children facing cancer can encounter even longer waits, as clinical trials typically begin with adults before being expanded to pediatric patients. This often means therapies become available to younger patients much later.
Health Minister Sylvia Jones said FAST was created to bridge these gaps and ensure patients are not left waiting when proven treatments exist.
“Speed matters when lives are on the line,” Jones said in a statement. “This program allows us to move faster, giving patients access to cutting-edge therapies while longer-term pricing discussions continue.”
The initiative enables Ontario to temporarily fund select cancer medications ahead of national cost negotiations, allowing treatment to begin sooner without compromising fiscal oversight. Officials say the province aims to accelerate approval for between seven and ten cancer drugs annually during the three-year pilot phase, after which the program’s effectiveness and sustainability will be reviewed.
Healthcare leaders welcome the move, describing it as a meaningful step toward closing long-standing treatment gaps and improving patient care across the province.
